Published in J Atr Fibrillation on February 29, 2016
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation (2013) 4.60
Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol (2014) 3.01
Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol (2014) 2.94
Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes (2012) 2.61
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart (2004) 2.56
Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol (2007) 2.32
Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm (2013) 2.19
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J (2005) 2.19
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J (2014) 1.54
Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace (2012) 1.53
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation (2013) 1.35
Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ (2008) 1.35
Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol (2006) 1.23
Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J (2016) 1.05
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart (2012) 1.05
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ (2012) 0.99
Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J (2012) 0.99
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One (2013) 0.93
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention (2015) 0.92
Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm (2015) 0.89
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. J Cardiovasc Med (Hagerstown) (2012) 0.87
The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Europace (2014) 0.80
Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years. Rev Port Cardiol (2013) 0.79
Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Rev Port Cardiol (2015) 0.78
A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation. Med Decis Making (2015) 0.77
Percutaneous left atrial appendage suture ligation: not ready for prime time. J Am Coll Cardiol (2014) 0.77
Ligament and vein of Marshall: A therapeutic opportunity in atrial fibrillation. Heart Rhythm (2015) 0.81
Effect of Age on Outcomes of Catheter Ablation of Atrial Fibrillation. J Atr Fibrillation (2013) 0.75